Company registration number 14574735 (England and Wales)
BILLESLEY PHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 JANUARY 2024
BILLESLEY PHARMA LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 3
BILLESLEY PHARMA LTD
BALANCE SHEET
AS AT
31 JANUARY 2024
31 January 2024
- 1 -
2024
Notes
£
£
Current assets
Stocks
10,150
Debtors
3
66,563
Cash at bank and in hand
35,468
112,181
Creditors: amounts falling due within one year
4
(125,036)
Net current liabilities
(12,855)
Capital and reserves
Called up share capital
100
Profit and loss reserves
(12,955)
Total equity
(12,855)
The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true
For the financial period ended 31 January 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved and signed by the director and authorised for issue on 1 October 2024
Kamran Sarwar
Director
Company registration number 14574735 (England and Wales)
BILLESLEY PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 JANUARY 2024
- 2 -
1
Accounting policies
Company information
Billesley Pharma Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 65 Woolmore Road, Birmingham, B23 7EB.
1.1
Reporting period
The reporting period is from 6 January 2023 to 31 January 2024. This ties in with the date of incorporation of the company.
1.2
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention.The principal accounting policies adopted are set out below.
1.3
Going concern
Atruet the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.
1.4
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
1.5
Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.
1.6
Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.
2
Employees
The average monthly number of persons (including directors) employed by the company during the period was:
2024
Number
Total
5
BILLESLEY PHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 JANUARY 2024
- 3 -
3
Debtors
2024
Amounts falling due within one year:
£
Trade debtors
52,716
Other debtors
13,847
66,563
4
Creditors: amounts falling due within one year
2024
£
Trade creditors
73,146
Other creditors
51,890
125,036
5
Related Party Disclosures
As at 31 January 2024 the following balances, included in other creditors due within one year, were due to related companies:
Rhodium Pharma Ltd: £10,000
Twilight UK Ltd: £10,000
The above balances are repayable on demand.
6
Ultimate Controlling Party
The controlling party is Kamran Sarwar.